Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Exclusion Criteria

• •Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular,psychiatric,musculoskeletal, genitourinary,immunological,dermatological,endocrine, connective tissue diseases or disorders.
• •Subjects who had a clinically relevant surgical history.
• •Subjects who had any significant abnormality in the coagulation tests.
• •Subjects who had any significant abnormality in the liver function tests (a case-by-case decision for any abnormality was to be discussed with the Sponsor before inclusion).
• •Subjects who had a history of relevant atopy or drug hypersensitivity.
• •Subjects who had a history of alcoholism or drug abuse.
• •Subjects who consumed more than 14 units of alcohol a week.
• •Subjects who had a significant infection or known inflammatory process at screening or admission to each treatment period.
• •Subjects who had acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period.
• •Subjects who had received fluoxetine within 5 weeks of admission to the first period.
• •Subjects who had used any other medicines within 2 weeks of admission to first period that could affected the safety or other study assessments, in the investigator's opinion.
• •Subjects who had previously received BIA 9-1067.
• •Subjects who have used any investigational drug or participated in any clinical trial within 90 days prior to screening.
• •Subjects who have donated or received any blood or blood products within the 3 months prior to screening.
• •Subjects who were vegetarians, vegans or have medical dietary restrictions.
• •Subjects who could not communicated reliably with the investigator.
• •Subjects who were unlikely to co-operate with the requirements of the study.
• •Subjects who were unwilling or unable to give written informed consent.
• •(If female) She was pregnant or breast-feeding.
• •(If female) She was of childbearing potential and she did not use an approved effective contraceptive method (double-barrier, intra-uterine device) or she uses oral contraceptives.